Lilly (LLY. N) U.S. stocks widened their premarket decline to 11 percent after experiments showed that Lilly's oral drug Orforglipron lost an average of 11.2 percent in weight.
2025-08-07 10:31:30
Lilly (LLY. N) U.S. stocks widened their premarket decline to 11 percent after experiments showed that Lilly's oral drug Orforglipron lost an average of 11.2 percent in weight.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
